The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Chimeric antigen receptor (CAR) technology has revolutionized cancer treatment, particularly in malignant hematological tumors. Currently, the BCMA-targeted second-generation CAR-T cells have showed impressive efficacy in the treatment of refractory/relapsed multiple myeloma (R/R MM), but up to 50%...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Deming, Wang, Keke, Wei, Cheng, Feng, Dudu, Liu, Yonghua, He, Qingyan, Xu, Xing, Wang, Chunling, Zhao, Shuping, Lv, Leili, Long, Jing, Lin, Danni, Zhao, Ai, Fang, Bingmu, Jiang, Jinhong, Tang, Shixing, Gao, Jimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985831/
https://www.ncbi.nlm.nih.gov/pubmed/33767695
http://dx.doi.org/10.3389/fimmu.2021.609421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985831/
https://www.ncbi.nlm.nih.gov/pubmed/33767695
http://dx.doi.org/10.3389/fimmu.2021.609421

Ejemplares similares